National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 2112 [2015-00497]
Download as PDF
2112
Federal Register / Vol. 80, No. 10 / Thursday, January 15, 2015 / Notices
rljohnson on DSK3VPTVN1PROD with NOTICES
• HHS Reference No. E–042–2012/0–
US–06—U.S. Patent Application No. 14/
370,140 filed July 1, 2014.
• HHS Reference No. E–201–2012/0–
PCT–02—PCT Application No. PCT/
US2013/069796 filed November 13,
2013, which published as WO 2014/
078350 on May 22, 2014.
Licensing Contact: Surekha Vathyam,
Ph.D.; 301–435–4076; vathyams@
mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute,
Molecular Targets Development
Program, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize aza-englerin analogues as
cancer inhibitors. For collaboration
opportunities, please contact John D.
Hewes, Ph.D. at john.hewes@nih.gov.
Nicotine Conjugate Treatment for
Parkinson’s Disease
Description of Technology: It has been
known since 1959 that tobacco use has
protective effects against Parkinson’s
disease. However, efforts to turn that
knowledge into a safe and effective
treatment, divorced from tobacco use,
have had little success. An inventor at
FDA now has in vitro evidence that
nicotine promotes a protein clearance
system, thereby halting Parkinson’s
disease progression. In addition to using
nicotine as the treatment, the inventor
has created a coated conjugate of
nicotine and nanoceria. This conjugate
not only harnesses the power of nicotine
but also takes advantage of the antioxidant effect of the nanoceria to reduce
the oxidant environment, which is also
a major mechanism of neuronal damage
in Parkinson’s disease.
Potential Commercial Applications:
Treatment for Parkinson’s disease.
Competitive Advantages: Improved
mechanism to use nicotine as a
treatment.
Development Stage:
• Early-stage
• In vitro data available
Inventor: Syed Z. Imam (FDA).
Intellectual Property: HHS Reference
No. E–016–2014/0—U.S. Provisional
Application No. 62/010,033 filed June
10, 2014.
Licensing Contact: Jaime M. Greene,
M.S.; 301–435–5559; greenejaime@
mail.nih.gov.
Collaborative Research Opportunity:
The FDA National Center for
Toxicological Research, Division of
Neurotoxicology, is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize A Nicotine-NanoCeria
VerDate Sep<11>2014
14:13 Jan 14, 2015
Jkt 235001
Conjugate named NIC–NANO for
treatment of Parkinson’s disease. For
collaboration opportunities, please
contact Syed Z Imam at syed.imam@
fda.hhs.gov.
cGAP–PNA Multivalent Ligand Display
at the Nanoscale
Description of Technology: Scientists
at the NIH are developing new types of
peptide nucleic acids (PNAs) that
maintain aqueous solubility at longer
lengths. This new type of PNA is called
‘‘cGAP–PNA’’ because it contains a
sequence complementary to the L–PNA
sequence, which is a PNA with one or
more gamma-sidechains that displays a
ligand. The investigators have
synthesized cGAP–PNAs that are 60
nucleobases long that can support the
assembly of 5 complementary L–PNAs
(each with 12 nucleobases) that bear
specific ligands. This platform can
replace more traditional multivalent
scaffolds, such as dendrimers and gold
nanoparticles.
Potential Commercial Applications:
Multivalent ligand display.
Competitive Advantages:
• Decreased hydrophobicity
• Increased water solubility
• Can be used at very long lengths
• More stable and resistant to
degradation than existing PNAs
Development Stage:
• Early-stage
• In vitro data available
Inventors: Daniel H. Appella, Andrew
V. Dix, Ethan A. Englund, Kara M.
George Rosenker (all of NIDDK).
Publication: Dix A, et al.
Programmable nanoscaffolds that
control ligand display to a G-proteincoupled receptor in membranes to allow
dissection of multivalent effects. J Am
Chem Soc. 2014 Sep 3;136(35):12296–
303. [PMID 25116377].
Intellectual Property: HHS Reference
No. E–761–2013/0—U.S. Provisional
Application No. 61/929,893 filed
January 21, 2014.
Related Technologies:
• HHS Reference No. E–308–2006/
3—U.S. Application No. 13/592,490
filed August 23, 2012.
• HHS Reference No. E–129–2010/
0—EP Application No. 11721899.0 filed
May 11, 2011; U.S. Application No. 13/
697,123 filed November 9, 2012.
Licensing Contact: Charlene S.
Maddox, Ph.D.; 301–435–4689;
charlene.maddox@nih.gov.
Collaborative Research Opportunity:
The National Institute of Diabetes and
Digestive and Kidney Diseases is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize this
PO 00000
Frm 00021
Fmt 4703
Sfmt 9990
technology. For collaboration
opportunities, please contact Marguerite
Miller at Marguerite.Miller@nih.gov or
301–496–9003.
Dated: January 9, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–00535 Filed 1–14–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Closure Devices for Transcaval Access to the
Abdominal Aorta.
Date: February 6, 2015.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7185, Bethesda, MD
20892, (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, 301–435–0725,
kristen.page@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: January 8, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–00497 Filed 1–14–15; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\15JAN1.SGM
15JAN1
Agencies
[Federal Register Volume 80, Number 10 (Thursday, January 15, 2015)]
[Notices]
[Page 2112]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-00497]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel, Closure Devices for Transcaval Access to the
Abdominal Aorta.
Date: February 6, 2015.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6701 Rockledge Drive, Room
7185, Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Kristen Page, Ph.D., Scientific Review Officer,
Office of Scientific Review/DERA, National Heart, Lung, and Blood
Institute, 6701 Rockledge Drive, Room 7185, Bethesda, MD 20892, 301-
435-0725, kristen.page@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: January 8, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-00497 Filed 1-14-15; 8:45 am]
BILLING CODE 4140-01-P